Monash IVF Group Limited (MNIVF)
| Market Cap | 192.56M -4.8% |
| Revenue (ttm) | 179.69M -0.1% |
| Net Income | 10.11M |
| EPS | 0.03 |
| Shares Out | n/a |
| PE Ratio | 19.05 |
| Forward PE | 14.18 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 48,000 |
| Open | 0.4000 |
| Previous Close | 0.5100 |
| Day's Range | 0.4000 - 0.4000 |
| 52-Week Range | 0.4000 - 0.7400 |
| Beta | 0.38 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 24, 2026 |
About Monash IVF Group
Monash IVF Group Limited engages in the provision of assisted reproductive and specialist women imaging services in Australia and Malaysia. It offers diagnostic obstetric, gynecological ultrasound, and fertility treatment services. It also provides tertiary level prenatal diagnostic, and IVF treatment services. Monash IVF Group Limited was incorporated in 2014 and is headquartered in Richmond, Australia. [Read more]
News
Monash IVF Group Earnings release: Trading update
Monash IVF Group released its earnings on June 11, 2026, summarizing the period's financial results.
Monash IVF Group Earnings Call Transcript: H1 2026
Underlying NPAT reached AUD 10.4 million at the upper end of guidance, despite revenue and market share declines in domestic IVF. International and genetics segments showed growth, and margin recovery is targeted through price increases and operational efficiencies into FY 2027.
Monash IVF Group Quarterly report: H1 2026
Monash IVF Group has published its H1 2026 quarterly earnings report on February 25, 2026.
Monash IVF Group Slides: H1 2026
Monash IVF Group has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 25, 2026.
Monash IVF Group Earnings release: H1 2026
Monash IVF Group released its H1 2026 earnings on February 25, 2026, summarizing the period's financial results.
Monash IVF Group Transcript: AGM 2025
Revenue and EBITDA grew in FY2025 despite sector headwinds and adverse incidents, with no final dividend declared. Board renewal and leadership transition are underway, and strategic investments continue, while competitive pressures and risk management remain key focus areas.
Monash IVF Group Slides: FY 2025
Monash IVF Group has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 19, 2025.
Monash IVF Group Earnings Call Transcript: H2 2025
Underlying NPAT for FY2025 was AUD 27.4 million, with revenue up 7% and EBITDA up 5.6%, despite market share declines and industry headwinds. FY2026 guidance is for lower NPAT due to a 10% drop in new patient registrations, but mid-single-digit growth is expected to resume from FY2027.
Monash IVF Group Annual report: H2 2025
Monash IVF Group has published its H2 2025 annual report on August 21, 2025.
Monash IVF Group Slides: H2 2025
Monash IVF Group has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 21, 2025.
Monash IVF Group Earnings release: H2 2025
Monash IVF Group released its H2 2025 earnings on August 21, 2025, summarizing the period's financial results.